Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05649787
Other study ID # 2022/103
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 18, 2023
Est. completion date December 31, 2025

Study information

Verified date December 2023
Source Fundación para la Investigación del Hospital Clínico de Valencia
Contact Marta Peiró, PhD
Phone +0034 961973536
Email mpeiro@incliva.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective study, blinded for the evaluator, randomized (1:1:1:1) to receive standard management alone or combined with a program of training (aerobic alone or combined with strength exercises) that will be carried out in a single centre. After randomization, patients will be clinically evaluated. The primary endpoint (peakVO2) will be assessed by cardiopulmonary exercise testing (CPET) at 12 weeks. Patients with heart failure with preserved ejection fraction, functional class NYHA II-III, and chronotropic incompetence criteria will be enrolled. A sample size estimation [alfa: 0.05, power: 80%, a 15% loss rate, and at least a delta change of mean peakVO2: +2,4 mL/kg/min (SD±2)] of 80 patients (20 per arm) would be necessary to test our hypothesis.


Description:

Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent clinical entity that predominantly affects women >60 years old, whose incidence has increased in the last decade and has a complex and multifactorial pathophysiology. Chronotropic incompetence (CrI) has emerged as a crucial mechanism, particularly in patients older than 60 years, and is associated with more significant functional impairment. Supervised training programs in patients with heart failure and reduced ejection fraction and CrI have improved functional capacity and chronotropic response. However, we do not have evidence about the effects of a supervised training program on patients with HFpEF and CrI. This work aims to evaluate the effect of a supervised exercise program for 12 weeks in patients with HFpEF and CrI on peak oxygen consumption (peakVO2) and chronotropic response. This is a prospective study, blinded for the evaluator, randomized (1:1:1:1) to receive standard management alone or combined with a program of training (aerobic alone or combined with strength exercises) that will be carried out in a single centre. After randomization, patients will be clinically evaluated. The primary endpoint (peakVO2) will be assessed by cardiopulmonary exercise testing (CPET) at 12 weeks. Patients with HFpEF, functional class NYHA II-III, and CrI criteria will be enrolled. A sample size estimation [alfa: 0.05, power: 80%, a 15% loss rate, and at least a delta change of mean peakVO2: +2,4 mL/kg/min (SDĀ±2)] of 80 patients (20 per arm) would be necessary to test our hypothesis.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 31, 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Patients diagnosed with heart failure with preserved ejection fraction according to 2021 ESC guidelines for Heart Failure. - N-terminal pro-B-type natriuretic peptide (NT-proBNP) >125 pg/mL in the last month - Stable symptomatic heart failure patients (New York Heart Association functional class II-III/IV) during the last month - Age = 60 years old. - Blunted heart rate (HR) response during a maximal cardiopulmonary exercise testing (CPET), defined as a chronotropic index <0.62 if previous treatment with Beta-blockers or chronotropic index <0.80 in patients without beta-blockers. Chronotropic index= [HRpeak exercise - HRrest] / [220 - age - HRrest] Exclusion Criteria: - Inability to perform a valid baseline cardiopulmonary exercise test - Cardiac pacemaker - Significant primary moderate-to-severe valve disease - Effort angina or signs of ischemia during CPET - Primary cardiomyopathies - Cardiac transplantation - Any other comorbidity with a life expectancy of less than one year

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Supervised aerobic training
Supervised moderate to high-intensity interval aerobic training
Supervised aerobic plus low to moderate-intensity strength training
Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
Supervised aerobic plus moderate to high-intensity strength training
Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training

Locations

Country Name City State
Spain INCLIVA Valencia

Sponsors (1)

Lead Sponsor Collaborator
Fundación para la Investigación del Hospital Clínico de Valencia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak oxygen consumption Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We define maximal functional capacity as when the patient stops pedalling because of symptoms and the respiratory exchange ratio (RER) was >1. During exercise, patients will be monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) was defined as the highest value of VO2 during the last 20 seconds of exercise.
Primary outcome: changes in peak oxygen consumption between and within groups at 12-week Unit of measure of peak oxygen consumption: mL/kg/min
Peak oxygen consumption will be evaluated at first visit and after 3 months. We will evaluate peak oxygen consumption change from baseline.
Secondary Chronotropic response Heart rate (HR) response during the maximal cardiopulmonary exercise testing will be evaluated following the chronotropic index (CIx) formula. The chronotropic index is evaluated by the following formula, including heart rate at peak effort, heart rate at rest and age. Chronotropic index: (peak heart rate-rest heart rate)/ [220-age-rest heart rate)].
Secondary outcome: changes in chronotropic response in between and within groups at 12-week Heart rate unit: beats per minute Age unit: years The chronotropic index has no units of measure.
Chronotropic index will be evaluated at first visit and after 3 months. We will evaluate chronotropic index change from baseline.
Secondary Kansas City Cardiomyopathy Questionnaire Scales The Kansas City Cardiomyopathy Questionnaire includes 23 items that map to 7 domains: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life, and self-efficacy (the patient's understanding of how to manage their heart failure). All Kansas City Cardiomyopathy Questionnaire domains are scaled from 0 to 100, where scores represent health status as follows: 0 to 24, very poor to poor; 25 to 49, poor to fair; 50 to 74, fair to good; and 75 to 100, good to excellent.
A change of 5 points is considered to be a small but clinically important change, whereas changes of 10 and 20 points are considered moderate-to-large and large-to-very-large clinical changes.
The Kansas City Cardiomyopathy Questionnaire will be evaluated at first visit and after 3 months. We will evaluate the Kansas City Cardiomyopathy Questionnaire change from baseline.
See also
  Status Clinical Trial Phase
Suspended NCT05839730 - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05095688 - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting NCT06379152 - Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Recruiting NCT05676684 - Dapagliflozin, Spironolactone or Both for HFpEF Phase 2/Phase 3
Recruiting NCT04153136 - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study) Phase 2
Recruiting NCT06114498 - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting NCT05715697 - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT04745013 - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart N/A
Completed NCT05586828 - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Completed NCT05126836 - Cilostazol for HFpEF Phase 2
Recruiting NCT04594499 - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting NCT05204238 - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed NCT04535726 - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting NCT03550235 - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed NCT04633460 - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure Phase 2
Completed NCT06228807 - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting NCT05284617 - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF Phase 2
Recruiting NCT05562063 - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients Phase 4
Recruiting NCT06027307 - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Phase 3
Withdrawn NCT05322616 - Single-Ascending Dose Study of JK07 in Subjects With HFpEF Phase 1